Exhibit 99.2

Harnessing the Power of Proteomics LEADING AI - DATA DRIVEN PROTEIN PLATFORM Global commercial and technological leader for bio - pharma and clinical protein discovery, measurement and interpretation November 2021

Forward Looking Statements ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. 2 Certain information, particularly relating to the future of Somalogic , our strategy, our product development plans, and the size and growth potential of the markets for our products and services, constitute forward - looking statements within the meaning of the Private Securities Litiga tion Reform Act. Forward - looking statements may generally contain words such as “believe,” “may,” “could,” “will,” “possible,” “can,” “estimate,” “continue,” “ongoing,” “consider,” “intend,” “indicate,” “plan,” “project,” “expect,” “should,” “would,” or “assume” or variations of such words or oth er words with similar meanings. We caution that these forward - looking statements are subject to numerous assumptions, risks and uncertainties that change over t ime and may cause actual results to differ materially from the results discussed in the forward - looking statements. These risks and uncertainties include our ability to obtain and maintain regulatory approvals, changes in applicable laws or reg ulations, changes in the life sciences industry, our ability to raising sufficient financing as and when needed; our ability to maintain existing lice nse agreements and manufacturing arrangements, our ability to protect our intellectual property, competitive risks, and those other risk factors id entified in the “Risk Factors” section of the Prospectus filed with the Securities and Exchange Commission (the “SEC”) on October 18, 2021, as well as subse que nt annual and periodic reports filed with the Securities and Exchange Commission, all of which are available at www.sec.gov and www.somalog ic. com. Forward - looking statements are based on current expectations and assumptions and currently available data and are neither predic tions nor guarantees of future events or performance. Current results may not be predictive of future results. You should not place considerable reliance on forward - looking statements which speak only as of the date hereof. We do not undertake to update or revise any forward - looking statements after they are made, whether as a result of new informati on, future events, or otherwise, except as required by applicable law.

Change ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. An evolutionarily advanced technology platform, database and bioinformatics capability Market - validated - more than 300 customers and collaborators Proteomics knowledge leadership with launch of clinical diagnostic applications Proteomics enablement leader – 7000 proteins, moving to 10,000 Significant technology trajectory and revenue acceleration ahead &UHDWHGE\$JQL IURPWKH1RXQ3URMHFW &UHDWHGE\0DVVLPR,SSROLWR IURPWKH1RXQ3URMHFW 3

Genomics provides the code, but proteins are the primary functional and structural molecules of life. We have been able to read DNA to full genome coverage at ever decreasing cost and increasing speed. However, we have not — until SomaLogic — been able to measure a sufficient number of proteins (thousands) simultaneously to obtain a “signal” and understand it. DNA Hereditary material that encodes functional biological molecules ONE AND DONE mRNA Molecule that carries DNA “directions for protein synthesis ~200K Transcripts Genomics Are The Blueprint, But Proteomics Are Dynamic Structure And Function ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. STATIC Primary functional and structural molecules for all biological processes Proteins REPEAT REGULARLY >1M Proteins ~10% HUMAN PROTEOME TRANSLATED 4 Is this missing a “ ~20KGenes

Leader in Enormous Untapped Proteomics Market EXPANDING PROTEOMICS AND GENOMICS MARKETS VIA UNBIASED, DEEP, AND RAPID PROTEOMICS AT SCALE ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. DIAGNOSTIC APPLICATIONS TRANSLATIONAL RESEARCH & BIOPHARMA DEVELOPMENT BASIC RESEARCH & DISCOVERY $ 40 B $ 20 B $ 30 B ~$ 90 B Total Available Market 5

Proteomics Leader: Significant First Mover Advantage 6 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. 20 YEARS 250 PUBLICATIONS ESTABLISHED INDUSTRY ADOPTION | RAPIDLY GROWING REVENUE BASE & DEEP DIAGNOSTIC PIPELINE MOST SAMPLES FIRST CLINICAL TESTS IN MARKET LARGEST CUSTOMER BASE 300 + CUSTOMERS $ 550 M + 450 K SAMPLES INVESTED $ 55 M REVENUE 2020 CAGR NEXT 5 YEARS 10 x SIZE DATABASE (than nearest competitor) + 100 FIRST - IN - CLASS PROTEIN PATTERNS 20 VALIDATED CLINICAL TESTS 40 % + 250 K DEEP CLINICAL SAMPLE

• Proprietary aptamers ~700 patents issued or pending • Largest panels in the industry by 4.5x • 7,000+ plex today 10,000 in 2022 • Unparalleled sensitivity/specificity, dynamic range, reproducibility & scale • No upper limit to number that can be created (1.2 x 1,064 possible shapes) ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. • Largest proteomics database with deepest understanding of the proteome • 450,000+ samples growing to 1.5M+ by 2024 • 80% of samples on 5,000+ plex • 40% annotated with clinical data • Biobank contracts and unique access • Clinical partnerships expand database and fuel test development • Unmatched regulatory resource • 10+ year track record of protein data product development • Access to >1B protein measurements and 15M clinical data points • Bespoke protein bioinformatics capabilities p roteomic bioinformatics and analytics as a service (expands business model and customer access) • Artificial Intelligence and machine learning expertise PROPRIETARY | BROAD | DEEP SENSITIVE | SPECIFIC SCALE | TIME | INPUTS KNOWLEDGE AI - POWERED | APPLICATION ANALYSIS | DEVELOPMENT The Leading Proteomics Platform TECHNOLOGY &UHDWHGE\$]DP,VKDT IURPWKH1RXQ3URMHFW DATABASE &UHDWHGE\$JQL IURPWKH1RXQ3URMHFW AI - POWERED BIOINFORMATICS STACK 7

• Proven ability to measure >7000 proteins in a single sample from small biologic sample (30µl) • Capability to run assays simultaneously , at high throughput • Established CLIA/CAP certified lab infrastructure • Highly scalable, reproducible and market validated ADDRESSING KEY COMMERCIAL PROTEOMICS CHALLENGES B R EA D TH D EP TH SPEED CO S T SCALABILITY Antibodies Nanobeads / Mass Spec. Protein Sequencing REPRODUCIBILITY LOW SAMPLE SIZE DETECTION NO PARTIAL YES ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. OPPORTUNITY 8 SomaLogic’s Technology

9 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. TECHNOLOGY BIOINFORMATICS STACK DATABASE Data BioBank Drug Discovery Engine Clinical Trial Tools Life Sciences Research Market Companion Diagnostics BioPharma & Research Business 20 Validated Tests 10 Tests Launched Pipeline of 100+ First - in - class Tests Clinical Diagnostics Business &UHDWHGE\$]DP,VKDT IURPWKH1RXQ3URMHFW &UHDWHGE\$JQL IURPWKH1RXQ3URMHFW &UHDWHGE\$GULHQ&RTXHW IURPWKH1RXQ3URMHFW Platform Breeds Virtuous Cycle of Value Creation

Industry Evolution: From Enabler to Applications to Integrated Platforms 10 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. EMERGING EVOLUTION OF PROTEOMIC COMPANIES FOLLOWING GENOMICS TRAJECTORY Total commercial opportunity ~$90B Proteomics TAM ~$75B current market cap ~$65B current market cap ~$10B current market cap ~$70B Genomic TAM SomaLogic has the broadest technological capability and substantial first mover advantage in proteomics to not just enable to apply to clinical diagnostics, capturing both ends of the market GENOMICS ENABLING GENOMICS APPLICATIONS PROTEOMICS ENABLERS FULL - SPECTRUM PROTEOMICS PLATFORM

An Enabler and Applications Company Traversing Enormous Market Segments

SomaLogic Research – Broad Offering Across Basic and Translational Research Market WHAT WE OFFER THE LIFE SCIENCES RESEARCH MARKET 12 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. SomaLogic Research BASIC RESEARCH & DISCOVERY $30B TRANSLATIONAL RESEARCH & BIOPHARMA DEVELOPMENT $20B COMPANION & COMPLEMENTARY DIAGNOSTICS CLINICAL TRIALS PQTL TARGETS DRUG | VACCINE TARGET ID & DEVELOPMENT NEW BIOLOGIC INSIGHTS GENOMIC & PROTEOMIC DISCOVERY

300+ Deep Industry Partnerships Built Up Over 20 Years 13 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. Gates funded COVID19 research samples ($1M renewable grant from the $125M grant program) Other research with Gates (maternal health, child nutrition in medically developing world). July 2021 Ten - year deal to use SomaLogic’s platform for drug development Sample commitments of >60 - 70K/ yr over the next several years (long - term revenue visibility) Late 2019 $24M sample deal 2020 - 2021 Desire to “co - develop” Amgen tests of interest on SomaLogic platform July 2020 INDIVIDUAL INVESTIGATORS ACADEMIC LABS PHARMA DISCOVERY CLINICAL RESEARCH ORGANIZATONS PHARMA CLINICAL TRIALS MULTI - OMICS PROVIDERS CLINICAL COMMERCIAL RISK STRATIFIERS HEALTH SYSTEMS RECENT BUSINESS MOMENTUM AND VALIDATION

SomaLogic Clinical Diagnostic Market Positioning 14 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. SomaLogic Clinical DIAGNOSTIC APPLICATIONS $40B EARLY DETECTION RISK PREDICTION PATIENT / POPULATION RISK STRATIFICATION DISEASE PROGRESSION TREATMENT SELECTION / COMPANION DIAGNOSTICS / RESPONSE PREDICTION PROPRIETARY TEST DEVELOPMENT MULTI - OMIC PRODUCT DEVELOPMENT &UHDWHGE\$JQL IURPWKH1RXQ3URMHFW &UHDWHGE\5R\\DQ:LMD\D IURPWKH1RXQ3URMHFW SOMASIGNAL DIAGNOSTICS APPLIED ACROSS THE CONTINUUM

• What is the risk of a second cardiovascular event in 4 years if there has been a previous event ( no diagnostic test/algorithm currently exists) • ~15,000 participants have been evaluated by this test in 7 different clinical human sample studies • Performance exceeds any combination of traditional risk factors with 4 - year AUCs 0.72 - 0.84 • Calibration excellent across studies even with 5x event - rate differences (event free survival (top), event rate (bottom) • Geographically, racially and gender robust • Norway, US, Japan, multi - country… Men/Women/Black • Symptomatic, asymptomatic, heart failure +/ - , elderly without known disease • Sensitive to both increases and decreases of risk over time SomaSignal Tests SECONDARY CARDIOVASCULAR RISK EXAMPLE SomaLogic Clinical Case Study ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. 15

Clinical Pipeline: SomaSignal Tests PIPELINE AND CURRENTLY AVAILABLE TESTS 16 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. SomaLogic Clinical LAUNCHED Q4 2019 AVAILABLE 2020 - 2023 AVAILABLE 2024+ • Alcohol impact • Body fat percentage • Cardiorespiratory fitness/VO 2 max • Alcohol impact • Alzheimer’s/dementia risk • Biologic/functional age • Body fat percentage • Body weight trajectory • Bone mineral mass • Cardiorespiratory fitness/VO 2 max • Circadian cycle • Cognitive function • Cognitive trajectory • Depression/mood with aging • Diet change/hypertension correlation • Frailty • Grip strength with aging • Healthspan • Inflammatory load • Insulin sensitivity • Joint health • Lean body mass • Lifespan • Mental stress • Microbiome diversity • Physical activity • Reproductive health • Resting energy rate • Sleep quality • Smoking status • Social deprivation • Visceral fat • Cancer risk (top 15) • Coronary artery calcium surrogate • CV risk (all - comers multiple subtypes) • eGFR (kidney function) • GLP - 1 agonist response • Glucose tolerance • Functional status/ability with aging • Liver fat • Predict type II diabetes diagnosis with complications • Primary CV risk - 4 year • Secondary CV risk - 4 year SomaLogic Clinical • Cancer early detection • Cancer susceptibility (top 4) • CHF therapy sensitivity • Congestive heart failure prognosis • Congestive heart failure type • COPD risk/risk of progression • Kidney disease prognosis • NASH: 4 liver biopsy components • Pulmonary function • Rule - out symptomatic coronary heart disease • Statin adherence • Cancer susceptibility (top 4) • CHF prognosis • CHF type • Kidney disease prognosis • NASH: 4 liver biopsy components • Rule - out symptomatic coronary heart disease • Statin adherence • Coronary artery calcium surrogate • eGFR (kidney function) • GLP - 1 agonist response • Glucose tolerance • Liver fat • Predict type II diabetes diagnosis with complications • Primary CV risk - 4 year • Secondary CV risk - 4 year • Alcohol impact • Alzheimer’s/dementia risk • Biologic/functional age • Body fat percentage • Body weight trajectory • Bone mineral mass • Cardiorespiratory fitness/VO 2 max • Cognitive function • Healthspan • Insulin sensitivity • Lean body mass • Lifespan • Physical activity • Resting energy rate • Sleep quality • Smoking status • Social deprivation • Visceral fat • Lean body mass • Resting energy rate • Visceral fat • Glucose tolerance • Liver fat • Primary CV risk - 4 year • Secondary CV risk - 4 year KEY FOR TEST TYPE • Health/Wellness • Preventative Medical • Disease Management

Financial Profile

2021 Revenue Results 18 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. - 5.0 10.0 15.0 20.0 25.0 2020 2021 Revenue 1Q 2Q 3Q 2020 2021 2021 Y/Y Growth Quarter 1Q 2Q 3Q 1Q 2Q 3Q 1Q 2Q 3Q TOTAL REVENUE ($mm) 6.3 7.2 14.2 18.9 19.6 20.0 200% 172% 41%

Growth Strategy

Build, Buy, Partner: Expand Technology Stack & Distribution Channels Aggressively ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. STRATEGY ▪ “Double down” on first mover comprehensive commercial position ▪ Combination of partnerships, investments and acquisitions ▪ Several partnerships are already initiated Added Data Services Analytics Biobank BI NextGen Platforms Protein Seq NextGen Platforms Protein Seq 10K Plex+ Expand Applications Single Cell Intracellular “Box” More Deployable Hardware Reagents Proteo - Genomics Discovery and Clinical Products Tech Trajectory NGS Alt Arrays ORGANIC Internal R&D Partnerships INORGANIC Acquisitions Partnerships Target Discovery Large scale Assay Partnerships TBD TBD Licenses/ Royalties Test Development Reagents Diagnostic Partnerships TBD 20

Experienced Leadership Roy SMYTHE Chief Executive Officer Melody HARRIS President and COO Nebojsa JANJIC Chief Scientific Officer Alan WILLIAMS Chief Development Officer Angela BAKKER - LEE EVP Healthcare Market Tracy HERVEY EVP Research & Discovery Market Manda MORRIS VP Finance Steve WILLIAMS Chief Medical Officer Jason CLEVELAND Chief Technology Officer TBD Chief Strategy Officer Shuan BLAKEMAN Chief Financial Officer ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. 21

Board of Directors & Financial Partners Blue Water Life Science Advisors Boston Millennia Partners Mossrock Capital Monashee Investment Charles M. LILLIS Chairman Co - Founder & Partner, LoneTree Capital Anne MARGULIES Vice President & Chief Information Officer, Harvard University Eli CASDIN Chief Investment Officer and Founder, Casdin Capital Bob BARCHI M.D., Ph.D. Former President of Rutgers University Richard POST Former President & CEO, Autobytel, Inc. Roy SMYTHE CEO, SomaLogic Former CMO for Strategy & Partnerships, Royal Philips Ted MEISEL J.D. Executive Founder of AVIA Troy COX Former CEO of Foundation Medicine and SVP of U.S. BioOncology for Genentech Kevin CONROY J.D. Chairman and CEO of Exact Sciences Stephen QUAKE Ph.D. Lee Otterson Professor of Bioengineering and Professor of Applied Physics at Stanford University

SomaLogic Is Uniquely Positioned ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. • A proprietary platform (technology, database, bioinformatics) and a first - mover advantage • Twenty years experience, and more than 500M total investment in technology • More evolutionarily advanced position (enablement and applications) than any other proteomics company • Market validated – many customers, established products, revenue and more of each assured • The global leader in protein measurement, at 4.5X all competitors – 7,000 current, on the way to 10,000 • The world’s largest clinical proteomics database with ~500,000 samples, ~1/2 with full clinical correlation • The market leader in protein bioinformatics – 1B protein measurements and 15M clinical data points • Twenty validated first - in - class protein pattern recognition diagnostic tests, and ~100 in development • Core measurement reagent is nucleic acid, with significant technology trajectory options • A very senior management team, with experience in healthcare, data, R&D, genomics and engineering 23

Visit our website : www.somalogic.com Contact us: investors@somalogic.com 24

Appendix ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. 25

Health System Clinical Diagnostic Marker Progression ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. INVESTMENT IN COMMERCIAL INFRASTRUCTURE, NEW PRODUCT AND SERVICE OFFERINGS AND HEALTH SYSTEM PARTNERSHIPS C A B D Benefits proof studies were initiated with 4 health systems. A subset of customers will become the first purchasers, and others will fast follow those, by convention. CV Risk tests, others evaluated for health econ, subgroup applications (Ex: CV risk with chemo) C A B D TBA TBA TBA TBA C A B D TBA TBA TBA TBA 2020 2021 2022 2023 HEALTH SYSTEM PARTNERSHIPS 26

The SomaLogic Platform “SOMAMER” REAGENTS SOMASCAN ASSAY SOMALOGIC BIOINFORMATICS EXPERTISE Slow Off - Rate Modified(“SOMAmer”) Aptamers: proprietary protein - binding reagents Incorporates ~7,000 (current) unique SOMAmer reagents to measure proteins in a single sample World - Leading Biobanks Contracts and Access data Emerging Clinical Partnerships PROTEOMICS DATA PRODUCTS SOMASIGNAL TESTS SOMALOGIC PROTEOMICS DATABASE SomaSignal Research SomaSignal Clinical data ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. 27

SomaSignal Tests • First - in - class, only diagnostic tests using protein pattern recognition • Machine learning models correlate patterns of protein expression to condition or disease from thousands measured each time • Proteins chosen for each model (16 – 360) are chosen by the machine learning model, not by the literature SOMALOGIC BIOINFORMATICS EXPERTISE World - Leading Biobanks Contracts & Access data Emerging Clinical Partnerships PROTEOMICS DATA PRODUCTS SOMASIGNAL TESTS SOMALOGIC PROTEOMICS DATABASE SomaSignal Research SomaSignal Clinical data Approach more akin to radiomics (e.g., system finds models humans cannot see) than traditional protein diagnostics Nature Medicine (2019) – test development methodology ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. 28

® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. Evolving the SomaScan Platform NGS COGS MARGIN DEPLOYED ASSAY (“BOX”) 24 MOS The assay readout can be performed on alternative, less expensive arrays, or on NGS platforms (feasibility completed for both). Either of these approaches will significantly lower assay COGS and increase margin on all products . Within ~24 mos. either of these could be a part of a more modular deployed assay solution, adding on - premise hardware and reagents sales to current, primarily service model. PRESENT MANY OPTIONS AVAILABLE AND IN MOTION FOR TECHNOLOGY TRAJECTORY H’WARE & REAGENTS NEW ARRAY APPROACHES 29

® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. • All SomaSignal tests can be run from one sample (they are algorithms derived from one data source) • Tests are repeatable and can measure change over time • Will replace more invasive, more expensive & less convenient diagnostic approaches SomaSignal Tests – First Clinical Products LEVERAGING HIGH - PLEX MEASUREMENT, PROTEIN PATTERN RECOGNITION & MACHINE LEARNING SomaLogic Clinical 30

Data Perpetuates Innovative Healthcare Delivery Opportunities ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. SomaScan Variety of high - quality data inputs: clinical trials, biobanks, clinical relationships Providing the raw material for development of SomaSignal tests Creating a significant spectrum of value and benefit for life science discovery and healthcare delivery 31

SomaSignal NASH Panel • The world’s only non - biopsy source of all 4 components of NASH and NAFLD • 4 independent models trained against biopsy and pathology read • NAS score sensitivity from .77 to .93, and sensitive to change • Gold standard liver biopsy – clinical trials / diagnosis difficult due to risk, cost and aversion • Imaging exists, but only suggests fibrosis • Original test model - 3000 specimens from PIVENS, FLINT and large natural history studies • Further validation by the LITMUS consortium (Liver Investigation: Testing Marker Utility in Steatohepatitis) where performance was #1 out of 20 tested biomarker / biomarker combinations. FIBROSIS BIOPSY RESULT STEATOSIS BIOPSY RESULT SOMASIGNAL NASH PREDICTIONS RELATED TO BIOPSY RESULT (VALIDATION DATASET) INFLAMMATION BIOPSY RESULT BALLOONING BIOPSY RESULT SomaLogic Clinical Case Study THE “LIQUID LIVER BIOPSY” ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. 32